Hibarimicin E
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Enzyme inhibitors |
| Catalog number | BBF-00957 |
| CAS | |
| Molecular Weight | 1569.59 |
| Molecular Formula | C77H100O34 |
Online Inquiry
Description
Hibarimicin E is a tyrosine kinase inhibitor produced by Microbispora rosea subsp. hibaria.
Specification
| IUPAC Name | (2S,4S,5S,6R,7S,8R,9S)-15-[(6aR,7S,8R,9S,10S,10aS)-9-[(2R,5R,6S)-5-[(2R,5S,6S)-5-acetyl-5-hydroxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-7-[(2R,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-1,8,10,10a,12-pentahydroxy-3,4-dimethoxy-11-oxo-10-propyl-6a,7,8,9-tetrahydro-6H-tetracen-2-yl]-7-[(2R,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-6,9,12,19-tetrahydroxy-5-[(2R,5R,6S)-5-hydroxy-6-methyloxan-2-yl]oxy-16-methoxy-4-propyl-3-oxapentacyclo[9.8.0.02,8.04,9.013,18]nonadeca-1(11),12,15,18-tetraene-10,14,17-trione |
| Canonical SMILES | CCCC1(C(C(C(C2C1(C(=O)C3=C(C4=C(C=C3C2)C(=C(C(=C4O)C5=C(C(=O)C6=C(C7=C(C(=C6C5=O)O)C(=O)C8(C9C7OC8(C(C(C9OC1CC(C(C(O1)C)O)O)O)OC1CCC(C(O1)C)O)CCC)O)O)OC)OC)OC)O)O)OC1CC(C(C(O1)C)O)O)O)OC1CCC(C(O1)C)OC1CCC(C(O1)C)(C(=O)C)O)O |
| InChI | InChI=1S/C77H100O34/c1-12-19-74(95)71(109-40-17-15-38(27(4)102-40)106-41-18-21-73(94,30(7)78)31(8)105-41)61(90)64(107-42-24-36(80)53(82)28(5)103-42)34-23-32-22-33-45(55(84)44(32)69(92)76(34,74)96)56(85)49(67(100-11)63(33)98-9)48-57(86)46-47(60(89)66(48)99-10)58(87)50-51(59(46)88)70(93)77(97)52-65(50)111-75(77,20-13-2)72(110-39-16-14-35(79)26(3)101-39)62(91)68(52)108-43-25-37(81)54(83)29(6)104-43/h22,26-29,31,34-43,52-54,61-62,64-65,68,71-72,79-85,87-88,90-91,94-97H,12-21,23-25H2,1-11H3/t26-,27-,28+,29+,31-,34+,35+,36-,37-,38+,39+,40+,41-,42+,43+,52+,53+,54+,61+,62+,64-,65+,68-,71-,72-,73+,74-,75-,76+,77+/m0/s1 |
| InChI Key | QETQXVGQENIMIR-XVKMORKMSA-N |
Properties
| Appearance | Red Powder |
Reference Reading
1. Effects of hibarimicins and hibarimicin-related compounds produced by Microbispora on v-Src kinase activity and growth and differentiation of human myeloid leukemia HL-60 cells
Sung Ig Cho, Hidesuke Fukazawa, Yoshio Honma, Takayuki Kajiura, Hiroshi Hori, Yasuhiro Igarashi, Tamotsu Furumai, Toshikazu Oki, Yoshimasa Uehara J Antibiot (Tokyo). 2002 Mar;55(3):270-8. doi: 10.7164/antibiotics.55.270.
We studied the effects of hibarimicins and hibarimicin-related compounds produced by Microbispora rosea subsp. hibaria [glycosides (hibarimicins A, B, C, D, E, G, H and I) and aglycon (hibarimicinone)] or compounds produced by its mutants [glycosides (HMP-P4 and -Y6), aglycons (HMP-P1 and -Y1) and shunt products (HMP-M1, M2, M3 and -M4)] on v-Src tyrosine kinase and growth and differentiation of human myeloid leukemia HL-60 cells. Among them, hibarimicin B was a strong and the most selective v-Src kinase inhibitor with differentiation inducing activity of HL-60 cells. Hibarimicin E similarly induced HL-60 cell differentiation but had no v-Src kinase inhibitory activity. Hibarimicinone was the most potent v-Src kinase inhibitor, although less selective, and did not induce differentiation of HL-60 cells. Hibarimicin B competitively inhibited ATP binding to the v-Src kinase, but hibarimicinone showed noncompetitive inhibition. These two compounds, however, showed similar mixed types of inhibition against a Src substrate binding to the v-Src kinase. Altogether, these results suggest that signaling molecules other than Src might be more important in the differentiation induction of HL-60 cells.
Recommended Products
| BBF-03800 | Moxidectin | Inquiry |
| BBF-03816 | Milbemycin oxime | Inquiry |
| BBF-03781 | Resveratrol | Inquiry |
| BBF-04727 | Strigolactone GR24 | Inquiry |
| BBF-05880 | N-Me-L-Ala-maytansinol | Inquiry |
| BBF-02577 | Pneumocandin C0 | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
